These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 27068626)
1. Risk Factors for Nonplatelet Thromboxane Generation After Coronary Artery Bypass Graft Surgery. Kakouros N; Nazarian SM; Stadler PB; Kickler TS; Rade JJ J Am Heart Assoc; 2016 Mar; 5(3):e002615. PubMed ID: 27068626 [TBL] [Abstract][Full Text] [Related]
2. Nonplatelet thromboxane generation is associated with impaired cardiovascular performance and mortality in heart failure. Hariri E; Kakouros N; Bunsick DA; Russell SD; Mudd JO; Laws K; Lake MW; Rade JJ Am J Physiol Heart Circ Physiol; 2022 Jul; 323(1):H248-H255. PubMed ID: 35714178 [TBL] [Abstract][Full Text] [Related]
3. Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting. Zhu J; Zhu Y; Zhang M; Xue Q; Hu J; Liu H; Wang R; Wang X; Zhao Q J Thorac Cardiovasc Surg; 2022 Mar; 163(3):1030-1039.e4. PubMed ID: 32359899 [TBL] [Abstract][Full Text] [Related]
4. Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. Olson MT; Kickler TS; Lawson JA; McLean RC; Jani J; FitzGerald GA; Rade JJ J Thromb Haemost; 2012 Dec; 10(12):2462-9. PubMed ID: 23072449 [TBL] [Abstract][Full Text] [Related]
5. Significance of urinary 11-dehydro-thromboxane B Simeone P; Boccatonda A; Liani R; Santilli F Ageing Res Rev; 2018 Dec; 48():51-78. PubMed ID: 30273676 [TBL] [Abstract][Full Text] [Related]
6. Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial. Kulik A; Abreu AM; Boronat V; Kouchoukos NT; Ruel M J Card Surg; 2022 Mar; 37(3):563-570. PubMed ID: 34961950 [TBL] [Abstract][Full Text] [Related]
11. The Risk Factor Analysis for the Late Graft Failure of Radial Artery Graft in Coronary Artery Bypass Grafting. Hosono M; Murakami T; Hirai H; Sasaki Y; Suehiro S; Shibata T Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):32-38. PubMed ID: 30122739 [TBL] [Abstract][Full Text] [Related]
12. Contemporary Use of Embolic Protection Devices During Saphenous Vein Graft Intervention. Valle JA; Glorioso TJ; Schuetze KB; Grunwald GK; Armstrong EJ; Waldo SW Circ Cardiovasc Interv; 2019 May; 12(5):e007636. PubMed ID: 31014092 [TBL] [Abstract][Full Text] [Related]
13. The Predictive Effects of Clinical Hematological Changes on Saphenous Graft Patency after Coronary Artery Surgery. İyigün T; Kyaruzi MM; Timur B; Satılmışoğlu MH; İyigün M; Kaya M Braz J Cardiovasc Surg; 2019 Jun; 34(3):297-304. PubMed ID: 31310468 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial. Willemsen LM; Janssen PWA; Hackeng CM; Kelder JC; Tijssen JGP; van Straten AHM; Soliman-Hamad MA; Deneer VHM; Daeter EJ; Sonker U; Klein P; Ten Berg JM Am Heart J; 2020 Feb; 220():237-245. PubMed ID: 31884246 [TBL] [Abstract][Full Text] [Related]
15. Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial. Kulik A; Abreu AM; Boronat V; Ruel M J Thorac Cardiovasc Surg; 2019 Jan; 157(1):151-161.e1. PubMed ID: 30122341 [TBL] [Abstract][Full Text] [Related]